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During the past 50 years, The Journal of Investigative Dermatology has
played a pivotal role in the presentation of developing knowledge in
photobiology. In this review, I will attempt to summarize the impact of
the Journal on this field by focusing on key articles that have appeared
therein and by putting them into perspective as well as pointing toward
developing trends for the future.
In the summer of 1987, the editor of the JID provided a list of the 200
most cited articles that have appeared in the Journal since its inception.
Of these, I have selected 24 that relate to photobiology, and this excludes
the topic of melanin pigmentation. The major areas of photobiology
covered by these articles include psoralens and PUVA [1], sunburn [2],
phototoxicity and photoallergy [2], ultraviolet carcinogenesis [3], light
sources [4], solar urticaria [4], and photoimmunology [4]. These are
summarized in Table I. Of the 24 most cited articles, four were reviews
and 20 were scientific papers, nine of which were conducted in animals
and 11 of which were conducted in human subjects (Table II). Because of
space limitations, only psoralens/PUVA, phototoxicity /photoallergy, and
sunburn are discussed here.
PSORALENS/PUVA
The photosensitizing properties of the psoralens have been known since
antiquity, but it is only in the past 50 years that rigorous scientific inquiry
has delineated the photochemical and photobiologic features of this
fascinating class of compounds, most of which occur naturally. Much of
the credit for opening up this field must go to Fitzpatrick, Pathak, and
Lerner, who organized a major research effort with these compounds in
the 1950s and 1960s, which culminated in the introduction of PUVA
photochemotherapy for the treatment of psoriasis and other dermatologic
diseases in 1974 [4].
The paper by Lerner et al. described clinical and experimental studies
with 8-methoxypsoralen in the depigmenting disease vitiligo [5]. They
showed that it was possible to obtain repigmentation of areas of
leukoderma with the combination of orally administered 8-methoxypsor-
alen and sunlight. This confirmed the earlier studies of El Mofty and his
colleagues in Egypt with the same approach [6]. In additional studies,
Pathak et al. [3] explored the effect of chemically altering the psoralen
molecule on its ability to elicit erythema in human skin (Table III).
Furthermore, it was shown that the action spectrum for psoralen-induced
erythema was in the UVA portion of the solar spectrum [2,7].
Assessment of the photochemistry of psoralens showed that they
could intercalate into the base stack of DNA and, after longwave UV
radiation, form cycloaddition products with pyrimidine bases [8]. Further
irradiation led to the formation of cross-links [1,9]. A series of studies
quickly followed in which psoralen and UVA were shown to inhibit DNA
synthesis [10,11]. Walter et al. [12] then showed that psoralen and black
light (UVA) inhibited DNA synthesis in the skin of hairless mice.
Thereafter, this was subsequently confirmed, and the inhibiting effect on
epidermal DNA synthesis was shown to persist for only 24 h, after which
it returns to normal [13]. The combination of 8-methoxypsoralen and
UVA was then shown to promote sister-chromatid exchanges in cultured
human lymphocytes [14]. It was speculated that such exchanges could
represent evidence for DNA damage by PUVA. It was then shown that
in vivo there was no increase in sister-chromatid exchanges, but the
reasons for the conflicting data from in vitro and in vivo studies remain
unresolved [15].
The clinical application of the inhibitory effect of psoralen and UVA
on DNA synthesis to a disease like psoriasis, in which epidermal
hyperproliferation occurs, became a reality in the early 1970s [4]. A
major advance was the availability of potent artificial light sources with
sufficient intensity of emission in the UVA range to permit delivery of
controlled phototoxic (inhibitory to DNA synthesis) doses to the entire
body surface in relatively brief time periods. Subsequently, Melski et al.
[16] published the results of a cooperative clinical trial among 16 centers
in the United States to assess the safety and efficacy of PUVA
photochemotherapy in psoriasis. A total of 1308 patients were treated,
0022-202X/89/$03.50 Copyright & 1989 by The Society for Investigative Dermatology, Inc.
25S
REVIEW ARTICLE
Table I. Most Cited Articles in Photobiology,
Published in the JID 1937–1987
Ranka Year First Author Topic
3 1977 Melski Psoralens/PUVA
11 1970 Cleaver Carcinogenesis
24 1981 Aberer Photoimmunology
32 1972 Cleaver Carcinogenesis
46 1970 Greaves Sunburn
48 1953 Lerner Psoralens/PUVA
81 1965 Daniels Phototoxicity/photoallergy
85 1959 Griffin Psoralens/PUVA
91 1939 Epstein, S. Phototoxicity/photoallergy
93 1969 Berger Light sources
109 1960 Pathak Psoralens/PUVA
111 1974 Snyder Sunburn
112 1972 Harber Phototoxicity/photoallergy
118 1962 Pathak Psoralens/PUVA
131 1959 Fowlks Phototoxicity/photoallergy
133 1972 Mathur Sunburn
146 1976 Carter Psoralens/PUVA
147 1978 Fritsch Psoralens/PUVA
160 1963 Harber Solar urticaria
178 1959 Griffin Psoralens/PUVA
179 1959 Urbach Carcinogenesis
184 1968 Willis Phototoxicity/photoallergy
192 1981 Anderson Sunburn
195 1968 Johnson Sunburn
aAmong the 200 most cited articles as of mid-1987.Department of Dermatology, Case Western Reserve University, University
Hospital and VA Medical Center, Cleveland, Ohio, U.S.A.
and of these, psoriasis cleared in 88% and failed to clear in 3% (Fig 1).
Nine percent dropped out of the study for various reasons. The
importance of maintenance treatments for sustained clearing of the
disease was stressed (Fig 2). The acute toxicity of the modality included
erythema, nausea, pruritus, headache, and dizziness, all of which were
readily controllable in most patients. Similar results were reported
subsequently in a European cooperative trial that employed a more
aggressive protocol [17]. Clearing was achieved with a mean of 20
treatments and the total dose of UVA energy averaged 96 J/cm2. The
major difference in these two trials was the criterion for the initial dose of
UVA; in the U.S. study this was a fixed dose based on skin type, and in
the European study, the initial dose was determined by defining the
minimal phototoxic dose.
Because of concern about the potential chronic toxicity of PUVA
therapy, efforts have been aimed at identifying modalities that can reduce
the number of treatments required to achieve clearing and maintenance.
The study of Fritsch et al. [18] described the combination of an orally
administered retinoid (etretinate 1mg/kg/day) with a standard PUVA
protocol (Table IV). The combined treatments decreased the total UVA
energy required to achieve clearing of psoriasis and was effective in some
patients in whom PUVA alone had failed. It was concluded that
combined approaches offer attractive alternatives to monotherapy, both
to reduce toxicity and to enhance effectiveness [19]. In addition to
retinoids, PUVA has been combined with corticosteroids, anthralin,
methotrexate, and UVB [20].
Perspective
PUVA photochemotherapy has revolutionized the treatment of moderate
to severe psoriasis. Many of the basic scientific observations that
furthered its clinical use were published in the JID [3,5,7,14].
Furthermore, important publications regarding one of the major
cooperative clinical trials as well as the description of combination
therapy with PUVA appeared in the JID [16,18]. PUVA photochemother-
apy thus affords an excellent example of how knowledge about the
photochemistry and photobiology of the psoralens led to clinical trials
and finally to FDA approval of a modality that is a critical therapeutic
tool for the practicing dermatologist today. This represents a superb
example of one important role of a basic science journal; namely, to offer
an opportunity for, the publication of data that can form the basis of the
ultimate transfer of technology to the bedside.
As good as PUVA is, it is by no means a perfect treatment. There is a
need for more effective and less toxic furocoumarins that, in combination
with UVA, have less carcinogenic potential. Better topical agents with
less phototoxic potential could also prove to be quite useful. Light
sources that are more economical and that minimize the exposure time
required to elicit photosensitization are needed. Newer combinations
may further reduce toxicity and enhance efficacy.
Continuing vigilant monitoring of treated patients is essential,
particularly where cancer is concerned. The latent period for many
malignant neoplasms of environmental origin may be as long as 30–40 yr.
Because PUVA photochemotherapy has only been used for about 15 yr,
the incidence of skin cancers may continue to increase for some years.
PHOTOTOXICITY/PHOTOALLERGY
Knowledge that chemical substances in the environment, when
combined with sun exposure, can produce injury to the skin probably
dates to antiquity. Written documentation first appears in the Atharva
Veda, a sacred book in India written in 1400 B.C. or earlier, which
describes the use of extracts of certain plants applied to skin followed by
sun exposure for the treatment of vitiligo [21]. These extracts were
psoralens, and the erythema, blistering, and pigmentation described
therein suggests that the writers were familiar with what we now call
phototoxicity.
Little in the way of new knowledge regarding this phenomenon
became available until the beginning of the 20th century when
experiments conducted by Oscar Raab in Munich in the laboratory of
Professor H. Tappeiner showed that paramecia in irradiated solutions
containing photoactivated dyes were killed, whereas in the absence
of light or dye, no killing occurred [22,23]. The term used to describe
this process was photodynamic action and later studies confirmed that
oxygen was an obligate intermediate in this type of photosensitized
reaction.
It was subsequently recognized that although there is no common
chemical structure characteristic for agents that evoke photodynamic
action, all such agents possess a distinctive physical characteristic,
namely, fluorescence.
Studies verifying that photodynamic action can mediate pathologic
changes in human skin were first performed by Friedrich Meyer-Betz and
reported in 1913 [24]. He injected a solution of hematoporphyrin (acid
hydrolyzed bovine blood) into himself intravenously and then exposed
his skin to sunlight for a short time. Within hours he developed erythema
and edema with severe burning and pruritus that persisted for several
days without further sun exposure. He also came to regret his heroic self-
experiment when it became obvious that the abnormal reaction to
sunlight recurred with each subsequent exposure for several weeks. This
illustrated that porphyrms were capable of photosensitizing human skin
and that the phototoxic response can be repetitively elicited over time
when the photosensitizer remains bound to structures in the skin.
Subsequently, Blum and his associates [25] performed additional
experiments in which a photoactive dye was injected mtradermally into
the skin of human subjects and these sites then exposed to sunlight. An
immediate severely pruritic wheal developed and it was suggested that
Table II. Types of Research in Photobiology Described
ii the Most Cited Articles in The JID 1937–1987
Types of Articles Subjects
Ranka Reviews Equipment Scientific Animal Human
3 X X
11 X X
24 X X
32 X X
46 X X
48 X X
81 X X
85 X X X
91 X
93 X X
109 X X
111 X
112 X
118 X
131 X
133 X X X
146 X X
147 X X
160 X X
178 X X
179 X X
184 X X
192 X
195 X X
aAmong the 200 most cited articles as of mid-1987.
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the reaction had the characteristics of the so-called ‘‘triple-response’’ of
Lewis [26].
The sulfonamides were first introduced into clinical medicine in the
1930s and represented a revolutionary advance in the management of
certain infectious diseases. Not long thereafter, practicing dermatologists
drew attention to an unusual phenomenon in which some outpatients
with erysipelas treated with sulfanilamide developed a cutaneous
eruption on sun-exposed skin areas, whereas hospitalized patients
Table III. Effect of Structural Alterations on Erythemal Activity of Psoralen Molecule
Mean Erythemal Response after 18 and 36h
(% Reflectance Difference)
Micrograms per 2.5 cm2
Skin Area Standard
No. Compound Structure Erythema 5 10 25 50
Psoralen
25mg
8-MOP
25mg
Remarks Relative
Activity
1. Psoralen Visible ± ++ +++ ++++ ++ ++++
2. 4-Methylpsoralen Green filter 3 6 7 11 5
Visible + ++ +++ ++++ +++ ++ ++++
3. 50,8-Dimethylpsoralen Green filter 3 7 11 11 9 7
Visible ± + +++ ++++ +++ ++ ++++
Green filter 3 3 7.5 10 9 7
4. 4,50,8-Trimethylpsoralen Visible ± + +++ ++++ +++ ++ ++++
Green filter 2 5 7.5 11 7 6
5. 8-Methoxypsoralen Visible  ± ++ +++ +++ +++
Green filter 1 2 6.5 8 7
From ref. [3].
Figure 1. Probability of patients having psoriasis as a function of the number
of clearing treatments. Selected cases of treatment schedules as shown, as
well as the 95% confidence band for all selected cases. The curve for all cases
without exclusion is also shown. From Ref. [16].
Figure 2. Probability of remaining clear of psoriasis as a function of weeks on
maintenance. Four maintenance schedules are shown as well as the 95%
confidence band for all cases collectively. From Ref. [16].
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Table V. Comparison of Primary Photosensitization and Allergic Sulfanilamide-Light Reaction
PR LR
1. Occurrence of reaction In all (6) test persons, at the first exposure
(22 experiments)
Only in 2 out of 6 test persons, after an interval of 10 days from
the appearance of the first primary reaction; and in these two
persons after each subsequent test (26 experiments)
2. Type of reaction
a. Characteristics Erythema of several days’ duration followed
by pigmentation
Urticarial inflammatory reaction without apparent
pigmentation, lasting for 10-14 days
No swelling Swelling and infiltration
No wheal formation after rubbing Wheal formation after rubbing
b. Size 0.8–1.0 cm, in diameter 1.5–4.0 cm, in diameter
c. Configuration Round or kidney-shaped At site of primary reaction similar to it in form. At new sites more
or less round, with or without lymphangitic (?), finger-like
spread
d. Subjective symptoms None Intense pruritus
e. Comparison with ordinary ultraviolet
erythema
Only quantitative differences Entirely different
3. Conditions of reaction
a. Amount of sulfanilamide Increased reaction with increase of dose.
Larger amount necessary for primary reaction.
0.01 cc not effective
Increased reaction with increase of dose 0.01 cc effective
b. Amount of ultraviolet Degree of reaction increased with dosage
(to some extent)
Degree of reaction increased with dosage
Quartz lamp At least mild erythema dose necessary Suberythema doses sufficient. Frac13; of the amount necessary
for a primary reaction effective
Natural sun light Appeared more effective than quartz lamp Natural sunlight more effective. Reaction produced even by
diffuse light on a hazy day
c. Time interval between injection and
irradiation. The latter had to follow
Within at least 3–4 h Within at least 6–8 h
d. Injection of sulfanilamide irradiated
in vitro (with or without human serum)
Not effective Not effective
e. Irradiation of skin previous to injection Not effective Not effective
f. Effect of ultraviolet without injection No abnormal reaction No abnormal reaction
g. Effect of sulfanilamide without light
(injection and patch test)
Not effective (24 experiments) Not effective (19 experiments), except in 2 out of 10 instances
where sulfanilamide was injected, simultaneously with
irradiation of another site
4. Influence of previous reactions on further
injections
a. Local reinjection Apparently not different Shortening of incubation period, peak and duration of reaction
b. General effect Apparently always same under same
circumstances
Change in allergic state apparent. Degree of hypersensitivity
decreasing after 2 months, but previous level reattained and
exceeded by subsequent experiments
5. Passive transfer Inconclusive
From Ref. [29].
Table IV. Clearing Phase Therapy: Retinoic Acid Derivative-PUVA Combination Compared With Standard PUVA
Regimen
Duration of PUVA Treatment (days) Irradiations Total Energy Applied to J/cm2
Standard PUVA (n=59) 27.8±15.2 14.3±7.8 93.2±80.6
Combined regimen plaque-type psoriasis subgroup 1 (n=27) 17.3±7.6 9.7±4.1 36.2±33.0
Combined regimen plaque-type psoriasis subgroup 2 (n=9) 11.0±6.7 6.3±3.5 22.6±31.2
Combined regimen palmoplanter psoriasis subgroup 3 (n=12) 12.8±5.5 7.0±3.0 21.4±17.3
From Ref. [18].
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treated identically had no such difficulty [27,28]. This observation
prompted Dr. Stephen Epstein at the Marshfield Clinic in Marshfield,
Wisconsin, to conduct a study in which 0.1 cc of a 1% solution of
sulfanilamide was injected intradermally and the sites irradiated at
various times up to 24h with a high-pressure mercury arc or natural
sunlight [29]. Epstein stated that ‘‘y an erythema dose of ultraviolet rays
produced in all [22] experiments an erythematous reaction of about
0.8–1.0 cm in diameter, contrasting with the milder erythema of the
surrounding skin.’’ This was clearly a phototoxic response. He went on to
describe a different reaction that occurred spontaneously in two of six
subjects after 10 d. ‘‘At this time, an inflammatory, urticarial reaction,
with intense pruritus developed spontaneously at the site of the primary
reaction.’’ This was said to be larger than the original response and to
persist for 10–14 d. Subsequent experiments in these two subjects
produced a similar reaction, but within 10–24h of testing and with 1/3
the dose of ultraviolet energy needed to evoke the phototoxic response.
Epstein postulated that he had succeeded in inducing a photoallergic
reaction to sulfanilamide in these subjects (Table V). This was a seminal
paper in investigative photobiology/dermatology because it challenged
the fundamental concept existing at the time that photodynamic
(phototoxic) reactions alone could explain cutaneous photosensitization.
It laid the groundwork for ensuing studies that culminated in
experimental evidence showing that photoallergy is a cell-mediated
response of the delayed type [30]. Recent studies indicate that
sulfanilamide induces both phototoxic and photoallergic reactions in
skin by free radical mechanisms that result in binding of the drug to
cystine residues in protein [31,32].
Another important paper in this field is that of Fowlks [33] who
provided an exhaustive review of all of the photosensitizers investigated
between 1930 and 1958 for their photodynamic effect. He pointed out
that aromatic amino acids in proteins appear to be particularly
susceptible to photodynamic action. It was concluded that excited
photosensitizers may lead to (1) chemical combination with a sensitive
cellular constituent, (2) oxidation of a sensitive cellular constituent, or (3)
indirect excitation. This exhaustive review provided a valuable summary
of existing knowledge at the time regarding photodynamic injury to
biologic structures.
The paper by Daniels [34] described a simple microbiologic method
for demonstrating phototoxicity. A suspension of Candida albicans was
plated on to Sabouraud’s dextrose agar plates and then the agent to be
tested added to small filter paper discs placed on the agar. The plates
were irradiated with filtered (longwave) ultraviolet, and the development
of clear zones around the disc was interpreted as a positive phototoxic
response. Unfortunately, the specificity and sensitivity of this test proved
to be somewhat less than satisfactory and its utilization has diminished in
recent years.
After Epstein’s delineation of photoallergy, an ‘‘epidemic’’ of
photoallergic contact dermatitis occurred in the United Kingdom as first
described by Wilkinson [35], who ascribed this to tetrachloro-salicyla-
nilide, an antibacterial compound added to soaps and other toiletries in
the 1960s. A small percentage of these photoallergic individuals
subsequently maintained persistent cutaneous sensitivity despite dis-
continuing all known exposure to the chemical. These individuals were
termed ‘‘persistent light reactors’’ and had, as one characteristic feature,
a lowered erythema threshold to UVB [36].
The mechanism of this reaction was unclear and prompted the studies
described by Willis and Kligman [37] in which they purported to show
that persistent photosensitivity was simply a manifestation of the
unsuspected persistence of the responsible chemical in the skin.
Photosensitization to a series of halogenated salicylanilides was induced
in healthy subjects using a modification of the maximization procedures
for the induction of ordinary contact allergy originally described by one
of these authors in the JID [38]. Photosensitized individuals were shown
to have increased amounts of the photosensitizer at the induction site as
verified by comparing the absorbance and fluorescence of ethanol
extracts of skin with those of authentic standard solutions and by
inducing positive photoreactions with the extracts in photosensitized
subjects. Extensive exposure of uninvolved skin, however, to appropriate
wavelengths of light does not evoke the reaction [39].
As with many concepts championed by Kligman, this was a provocative
hypothesis, the attractiveness of which was enhanced by its very simplicity.
Unfortunately, the mechanism of this reaction remains unknown. Although
the prolonged persistence of photosensitizing chemicals in sites of
maximization is plausible, the likelihood of this occurring with ordinary
use of agents containing such photosensitizers is virtually nil.
In 1972, Harber and Baer [40] reviewed the pathogenic mechanisms
of drug-induced photosensitivity and described several mechanisms for
such reactions, including drug phototoxicity, drug photoallergy, drug-
induced porphyria, drug-induced lupus erythematosus, and drug-induced
pellagralike eruption (Fig 3). This review was timely and provided a
unique perspective regarding the range of photosensitivity reactions
evoked by drugs and light. Fifteen years later, this remains a valuable
reference summarizing the state of the art of drug-induced photosensi-
tivity at that time.
Subsequent studies in mice have shown that photoallergic contact
dermatitis is a highly hapten-specific T-cell mediated delayed type
hypersensitivity [41]. All of these criteria are consistent with a
T-lymphocyte mediated process.
Perspective
During the past 50 years, a great deal of knowledge has accrued
regarding phototoxic and photoallergic reactions in the skin of
experimental animals and to a lesser extent in human skin, and many
advances were first published in the JID [29,33,34,37,40]. Challenges for
the future include identification of specific cutaneous structures at the
cellular, subcellular, and molecular level that are vulnerable to these
processes and the development of more sensitive techniques with which
to obtain unequivocal identification of the chemical structure of the
photosensitizer. Once such information becomes available, it should be
possible to design new photoprotective agents or to manipulate the struc-
ture of existing photosensitizing drugs to abrogate their photosensitizing
Figure 3. Hypothesis of mechanisms of phototoxic and photoallergic
reactions in photocontact dermatitis. From Ref. [40].
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potential. Better clinical management of phototoxicity and photoallergy
requires more effective photoprotective agents.
SUNBURN
As Blum [42] pointed out, knowledge that sunburn erythema of healthy
human skin is induced by ultraviolet radiation developed in the second
half of the 19th century. Studies in the early 20th century attempted to
define the capacity of the skin to absorb incident solar radiation.
Absorption spectra of human epidermis in vitro were shown to exhibit
maxima at 270–280nm and a minimum at 250–260nm, a pattern that
resembles the absorption spectrum of proteins [43]. It was also shown
that very little radiation shorter than 290nm penetrated through the
epidermis and that degeneration of cells in the prickle cell layer was a
characteristic histologic feature of sunburned human skin. It was also
clear that, because very little erythema-producing energy penetrates the
epidermis and there is a latent period of several hours between exposure
to erythema doses of ultraviolet energy and the development of visible
redness, a novel hypothesis was needed to fit these observations to a
mechanistic theory. Thus, it was generally agreed that ‘‘the initial
photochemical reaction brings about the elaboration in the epidermis of
a substance which migrates to the region of the minute vessels in the
papillary layer and brings about their dilation’’ [44].
The paper by Johnson and Daniels [45], in 1969, describes studies
designed to clarify the mechanism of sunburn in human skin. Ten
minimal erythema doses of ultraviolet energy were administered to
human subjects, and at varying times (1–24h) thereafter biopsies were
obtained and a histochemical technique was employed to assess the
stability of the lysosomes. This technique was thought to provide an
estimate of lysosomal instability by demonstrating acid phosphatase
activity. The results were interpreted as showing that sunburn was
associated with lysosomal membrane damage with release of hydrolytic
enzymes, and it was postulated that this could explain both the
development of dyskeratotic ‘‘sunburn’’ cells in the spinous layer as
well as sunburn itself, which was postulated to be the result of the release
of vasodilator substances from lysosomes (Fig 4). It is of interest that these
authors were also prescient in suggesting that the ‘‘fever which
accompanies severe sunburn may be due to the diffusion of these
substances into the dermis after massive damage to the epidermis.’’
Recent studies have shown that human keratinocytes irradiated with UVB
elaborate the cytokines interleukin-1 alpha and beta, which among other
things are known to induce fever (endogenous pyrogen) [46].
The paper by Greaves and Sondergaard [47], in 1970, examined the
inflammatory response to erythema doses of ultraviolet radiation in
human skin, using a perfusion technique that permits collection of
perfusates, which can then be analyzed for vasoactive substances. They
identified a smooth muscle-contracting agent in seven of 17 subjects that
was not histamine, serotonin, or acetylcholine. Kinins were found in both
control and irradiated subjects and thought not to be involved in
erythema production. Unfortunately, they did not speculate on the nature
of the inflammatory mediator in their paper. The paper by Mathur and
Gandhi [48], in 1972, reported that irradiation of rat skin with 2–8
erythema doses of ultraviolet energy produced a severalfold increase in
prostaglandin E in the epidermis and dermis as denned by a bioassay
procedure employing rabbit duodenum. These authors speculated
that the vasodilating substance previously isolated by Greaves and
Sondergaard might be prostaglandin E.
These observations led to the paper by Snyder and Eaglestein [49], in
1974, showing that injection of inhibitors of prostaglandin synthesis,
such as indomethacin and aspirin, into the skin of humans and guinea
pigs decreased and delayed the erythema response to 2–3 MED of
UVB (Table VI). Indomethacin was 45 times more effective than
aspirin in this regard. Control injections with equal volumes of saline
had no effect. Indomethacin was capable of blanching ultra-
violet erythema up to 18h after irradiation, suggesting that prosta-
glandins are synthesized continuously even after light exposure is
discontinued. These authors also correctly pointed out that their
study design did not unequivocally prove that prostaglandins mediate
sunburn erythema in human skin because they employed inhibitors
of the synthesis of the vasoactive substances and did not measure them
directly.
The precise sequence of events in the development of sunburn
erythema remains an enigma. Nonetheless, using more sensitive
techniques, considerable progress has been achieved in recent years in
directly measuring various vasoactive substances in skin irradiated with
ultraviolet energy [50,51]. Using a suction blister technique to obtain
fluids for measurement, Greaves and his associates [52] have employed
gas chromatography – mass spectrometry to identify these substances.
Early UVB erythema is associated with detectable increases in
prostaglandin E2 and prostacyclin (PGI) (as measured by detection of
its metabolite 6-keto PFGt alpha) as well as 12-hydroxyeicosatetraenoic
acid (12-HETE) [53,54]. This was confirmed by showing that topical
application of indomethacin causes suppression of erythema.
Figure 4. Formalin-fixed, paraffin sections of skin 24 h after exposure to 10
MED. Stained with Giemsa stain to show ‘‘sunburn cells.’’ From Ref. [45].
Table VI. Effect of Intradermal Indomethacin on UVR
Erythema
Dose
(mg)
Number
of Test
Sites
Number of
Blanched
Areas
Average
Intensity
Average
Duration
(h)
Human 0.1 5 1 1.0 1.5
Guinea pig 0.1 NT
Human 1.0 5 5 1.5 3.8
Guinea pig 1.0 7 4 1.8 3.4
Human 10.0 7 7 1.8 5.6
Guinea pig 10.0 9 9 2.2 4.6
Human 50.0 3 3 2.0 5.0
Guinea pig 50.0 4 4 3.0 6.2
Human 100.0 11 11 2.0 5.0
Guinea pig 100.0 30 30 3.0 5.3
NT=not tested. From Ref. [49].
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Studies with UVA erythema revealed increases in PGE2, PGD2, and
PGI, and a time course considerably different from that of UVB in that
these were increased earlier [55]. Furthermore, histamine was increased
fourfold by erythema doses of UVA. In summary it appears that UV
radiation (particularly UVB) produces PGE2, PGF2a, and 12-HETE in
keratinocytes, PGD2 in mast cells, and PGI2 in endothelial cells of the
dermal vasculature.
Perspective
Despite a remarkable increase in knowledge regarding various mediators
that participate in ultraviolet-induced erythema, much of which has been
published in the JID [45,47,48,55], there is still little or no understanding
of the specific chromosphore(s) that trigger this cascade. Furthermore, the
explosion of information concerning the local and systemic immunologic
effects of UVB in recent years suggests that there may be some
interconnection between such effects and the inflammatory events
occurring after skin irradiation. A major challenge for future research is
to identify the chromophore(s), to define the orchestration of these
seemingly isolated events, and to discover more effective topical and
systemic photoprotective agents to minimize the risk of sunburn
erythema.
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